Keywords: ardana/novartis, commence, marketing, emselex, uk, edinburgh, scotland-based
Ardana/Novartis commence marketing Emselex in UK
Article | 27 November 2006
Edinburgh, Scotland-based Ardana has commenced UK marketing of Emselex/Enablex (darifenacin), a novel M3-selective receptor antagonist for the once-daily ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
